GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Embecta Corp (FRA:JX7) » Definitions » Research & Development

Embecta (FRA:JX7) Research & Development : €78 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Embecta Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Embecta's Research & Development for the three months ended in Mar. 2024 was €17 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €78 Mil.


Embecta Research & Development Historical Data

The historical data trend for Embecta's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Embecta Research & Development Chart

Embecta Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23
Research & Development
56.30 52.13 53.81 67.57 79.83

Embecta Quarterly Data
Sep19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.64 20.86 22.11 18.52 16.93

Embecta Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Embecta  (FRA:JX7) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Embecta Research & Development Related Terms

Thank you for viewing the detailed overview of Embecta's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Embecta (FRA:JX7) Business Description

Traded in Other Exchanges
Address
300 Kimball Drive, Suite 300, Parsippany, NJ, USA, 07054
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.

Embecta (FRA:JX7) Headlines

No Headlines